STERIS plc (STE) fair value analysis
S&P 500 · Updated 2026-10-19
STE price how computed
Forward Fair Value verdict
UndervaluedSTE is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $214.40
- Sector
- Healthcare
- 12-month range
- $199.40–$268.65
- Market cap
- $20.9B
- From 52-week high
- -20.2%
- Shares outstanding
- 97.5M
- Rank in Healthcare by discount to fair value
- #25 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
STERIS plc is a healthcare company that provides sterilization and contamination control products and services for hospitals, surgical centers, and pharmaceutical manufacturers. The company operates globally with a significant presence in North America, Europe, and other international markets.
STE currently ranks #25 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $20.9B
- P/E (trailing)
- 21x
- Revenue (TTM)
- $6.04B
- Net margin
- 13.3%
- EPS (TTM)
- $10.42
- Gross margin
- 45.8%
- Debt / equity
- 0.28
- Revenue growth (3-yr avg)
- 6.9%
- Shares outstanding
- 97.5M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 70 · neutral
- 50-day average
- $221.35
- 200-day average
- $226.24
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Paid, last 12 months
- $2.58 per share (4 payments)
- Yield on last price
- 1.20%
- Consecutive years of increases
- 15
- Last ex-dividend date
- 2026-09-04
- Last payment date
- 2026-09-25
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 5 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+2.0%)
2026-03 ▼ miss (-0.7%)
2025-12 ▬ met (0.0%)
2025-09 ▲ beat (+3.8%)
2025-06 ▲ beat (+3.5%)
2025-03 ▲ beat (+5.4%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+0.5%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 2 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $259
- Target vs last price
- +20.8%
What our data shows for STE
- Our model validated 17 trailing price-to-earnings windows for STE, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $199.40–$268.65.
- The 14-day relative strength index sits at a neutral 70.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for STE
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent STE news
TickrTrends' derived news-sentiment signal for STE is currently leaning positive, computed from recent coverage.
- STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026 (manilatimes.net, 2026-10-20)
TickrTrends take: STERIS, a Healthcare sector company, is scheduled to discuss its fiscal 2027 second quarter results on November 5, 2026, providing an opportunity for investors to assess whether the company's operational performance justifies TickrTrends' current undervalued designation. Valuation-focused readers should monitor the company's revenue trends, margin performance, and forward guidance during this call to evaluate whether current market pricing reflects the company's fundamental strength. The quarterly results will be a key data point for determining if the undervaluation thesis remains supported or requires reassessment. - A Look at Steris PLC (STE) After 3.2% Gain -- GF Value $268.66 vs Price $224.33 (gurufocus.com, 2026-10-15)
TickrTrends take: Steris PLC trades at a meaningful discount to its GF Value estimate, with the current price approximately $44 below the derived valuation benchmark. The TickrTrends undervalued designation aligns with this gap, suggesting the stock may offer value relative to its fundamentals within the Healthcare sector. Investors focused on valuation metrics should monitor whether the stock moves toward the higher valuation target or whether the gap persists due to sector or company-specific headwinds. - STERIS plc (STE) to Acquire Xodus Medical for $2.1 Billion in Cash (gurufocus.com, 2026-10-14)
TickrTrends take: STERIS is acquiring Xodus Medical for a substantial cash outlay, representing a significant capital deployment that will influence the company's financial metrics going forward. Given the Healthcare sector's typical valuation multiples and STERIS's current TickrTrends assessment of undervaluation, investors should monitor how this acquisition affects the company's leverage ratios, free cash flow generation, and earnings accretion in subsequent quarters. The timing and integration success of this transaction will be critical factors in determining whether the current undervaluation thesis remains intact as the market reassesses the company's balance sheet and growth profile.
More STE news
- Steris: Anticipated M&A Has Taken Place, Gets My Thumbs Up (NYSE:STE) (seekingalpha.com, 2026-10-13)
- Steris (STE) Announces Acquisition of Xodus Medical to Expand Surgical Consumables Portfolio (gurufocus.com, 2026-10-12)
- STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-15)
- STERIS to Present at the Morgan Stanley Healthcare Conference (manilatimes.net, 2026-09-01)
What people are saying
Follow the STE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for STE showed movement this week as the RSI zone shifted from oversold to neutral territory. The stock maintains an undervalued valuation verdict according to current assessments. This shift in the RSI zone may suggest reduced selling pressure compared to the previous week's oversold conditions.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is STE stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), STE is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is STE's TickrTrends verdict?
STE's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does STE compare to other Healthcare stocks?
STE ranks #25 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is STE overbought or oversold?
STE's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does STE pay a dividend?
Yes. STE paid $2.58 per share over the last twelve months (4 payments), a 1.20% yield on TickrTrends' last price, and has raised the annual total for 15 consecutive years. The last ex-dividend date was 2026-09-04.
When does STE report earnings next?
STE's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does STE usually beat earnings estimates?
Over its last 8 reported quarters STE beat the consensus estimate 5 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about STE?
Of 9 analysts covering STE, 7 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $259 (+20.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
STE vs ABT · STE vs AMPH · STE vs CI · STE vs DVA · STE vs GEHC